Investment Rating - The investment rating for the company is "Buy" with a target price of 25.6 CNY, maintaining the current rating [2][4]. Core Views - The company is experiencing robust growth in performance, driven by globalization and new product launches. The revenue for 2024 is projected to reach 5.063 billion CNY, reflecting a year-on-year increase of 23.6% [2][10]. - The company has successfully implemented a global strategy, with overseas revenue growing by 27.45% in 2024, accounting for 27.54% of total revenue [10]. - The injection molding machine sector is seeing a recovery, with revenue from this segment reaching 3.555 billion CNY, a year-on-year increase of 28.8% [10]. Financial Performance Summary - Revenue (CNY million): - 2023A: 4,096 - 2024A: 5,063 (23.6% YoY growth) - 2025E: 5,847 (15.5% YoY growth) - 2026E: 6,705 (14.7% YoY growth) - 2027E: 7,741 (15.4% YoY growth) [6][12] - Net Profit Attributable to Parent Company (CNY million): - 2023A: 477 - 2024A: 608 (27.4% YoY growth) - 2025E: 751 (23.6% YoY growth) - 2026E: 907 (20.7% YoY growth) - 2027E: 1,101 (21.4% YoY growth) [6][12] - Gross Margin (%): - 2023A: 31.5% - 2024A: 31.9% - 2025E: 32.5% - 2026E: 32.9% - 2027E: 33.2% [6][12] - Net Margin (%): - 2023A: 11.6% - 2024A: 12.0% - 2025E: 12.8% - 2026E: 13.5% - 2027E: 14.2% [6][12] Market Performance - The company's stock price as of May 29, 2025, is 20.84 CNY, with a 52-week high of 28.91 CNY and a low of 16.28 CNY [2].
伊之密动态跟踪 —— 业绩稳健高增,全球化、新产品带来发展新机遇